Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
Turnstone Biologics Corp. (TSBX)
Company Research
Source: Yahoo! Finance
company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies,” said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. “The next frontier for TIL therapy is to extend its therapeutic activity in additional solid tumor indications beyond melanoma. Our differentiated approach includes a proprietary ‘cell selection' step which is designed to generate a TIL product that is dominated by tumor-reactive T cells. We believe this process is crucial to develop potent TIL-based therapies such as Turnstone's Selected TILs to address harder-to-treat, lower mutational burden cancers, such as colorectal cancer and other immunologically cold tumor
Show less
Read more
Impact Snapshot
Event Time:
TSBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSBX alerts
High impacting Turnstone Biologics Corp. news events
Weekly update
A roundup of the hottest topics
TSBX
News
- Turnstone Biologics Corp. (NASDAQ: TSBX) had its price target lowered by analysts at Piper Sandler from $20.00 to $3.75. They now have an "overweight" rating on the stock.MarketBeat
- Turnstone Biologics Corp. (NASDAQ: TSBX) had its price target lowered by analysts at Bank of America Co. from $12.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewswire
- Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerGlobeNewswire
TSBX
Earnings
- 3/21/24 - Beat
TSBX
Sec Filings
- 8/14/24 - Form 10-Q
- 8/14/24 - Form 8-K
- 7/2/24 - Form 4
- TSBX's page on the SEC website